Read more about Lupin Ltd jumps nearly 3% on Business Standard. Lupin Ltd is quoting at Rs 1069.45, up 2.95% on the day as on 12:49 IST on the NSE. The stock is up 42.86% in last one year as compared to a 17.09% jump in NIFTY and a 65.52% jump in the Nifty Pharma index.
Stocks To Watch: Dixon Technologies, Sobha Ltd, Lupin, Bandhan Bank, NMDC The domestic stock markets are likely to open in the green after a day s paused due to positive cues from across the global markets.
Updated: January 07, 2021 10:03 pm IST
The domestic stock markets are likely to open in the green after a day s paused due to positive cues from across the global markets. Asian markets are looking up in early trading, Wall Street had a firm closing and early trends on SGX Nifty indicate a positive opening for the index in India, with a 74-points gain. At 7:30 am, the Nifty futures were trading at 14,254, higher by 74 points or 0.67 per cent on the Singapore Stock Exchange.
FDA approves Lupin s Empagliflozin, Metformin Hydrochloride ER tablets FDA approves Lupin s Empagliflozin, Metformin Hydrochloride ER tablets
07 January 2021 | News Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate
Source credit: Shutterstock
Lupin Limited, a global pharmaceutical company, announced that it has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended-Release (ER) tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, from the United States Food and Drug Administration, to market a generic equivalent of Synjardy® XR tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmac
bmrcมกราคม 7, 2021
The global diabetic neuropathy market will reach $ 8460.3 million by 2025.The
global diabetic neuropathy market is valued at approximately US $ 4680 million in 2016, projected to grow with a favorable growth rate of more than 6.80% over the forecast period for 2017. -2025 The growth of this market is largely attributed to a growing population of elderly people with diabetes mellitus.The increase in appropriate treatment options and increasing awareness about PDN are driving the demand for PDN drugs today. With only four drugs approved for the management of PDN (Lyrica, Cymbalta, Nucynta and Qutenza), there is a great opportunity for new and emerging market players to produce them. Based on an analysis of the marketed products, Lyrica had the highest market share in 2017 and will remain similar trends until 2026.
Lupin receives approval for Sulfamethoxazole and Trimethoprim Oral Suspension USP
Posted On: 2021-01-06 03:54:17 (Time Zone: Arizona, USA)
Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.
Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).